日本前瞻性多中心研究(JUSTICE注册)评估Zenith Alpha腹主动脉覆膜支架早期临床结果:12个月支架腿通畅率可接受
JUSTICE前瞻性多中心研究在23家日本医院纳入147例使用Zenith Alpha AAA行EVAR的患者,核心实验室分析CT。12个月时I/III型内漏0.8%、瘤囊增大>5mm 0.8%,II型内漏35.2%;晚期并发症9例(含5例支架腿闭塞,3.4%),免于晚期并发症率93.5%。
要点
- 12个月免于晚期并发症率为93.5%,含4例支架腿闭塞和1例支架腿狭窄(3.4%)。
- 12个月I/III型内漏仅0.8%,瘤囊增大>5mm仅0.8%,II型内漏达35.2%。
- 作者结论:早期结果满意,支架腿闭塞率可接受,需长期随访确认持续性。
核心结论
- 与近期报告相反,日本多中心前瞻性研究显示低剖面Zenith Alpha AAA早期临床结果满意,支架腿闭塞率可接受。
- 作者指出需长期随访确认这些结果的持续性。
研究设计与样本
- 前瞻性多中心研究,2020年7月至2021年10月在23家日本医院使用Zenith Alpha AAA行EVAR的全部患者。
- 所有CT图像在核心实验室分析。
- 晚期并发症定义为EVAR后>30天发生的任何动脉瘤相关事件,包括瘤囊增大>5mm及任何再干预。
- 无瘤囊增大或再干预的内漏不列为晚期并发症。
主要发现
- 共147例EVAR;平均年龄76.5±7.7岁,男性84.4%,平均动脉瘤直径52.4±9.2mm。
- 76例(51.7%)存在说明书使用违规,主要与近端瘤颈严重成角(>60°)相关。
- 术中并发症6例,额外术中处理62例,其中预防性肠系膜下动脉弹簧圈栓塞37例。
- 技术成功(最终造影无I或III型内漏)99.3%;12个月I/III型内漏1例(0.8%),瘤囊增大>5mm 1例(0.8%),II型内漏35.2%,瘤囊回缩>5mm 30.1%。
- 晚期并发症9例,12个月免于晚期并发症率93.5%,包括4例支架腿闭塞和1例支架腿狭窄(3.4%)。
临床怎么用
- 作者认为,谨慎使用Zenith Alpha Spiral-Z Endovascular Leg可获得满意的早期临床结果,包括可接受的支架腿闭塞率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Recent reports of the Zenith Alpha abdominal endovascular graft (Zenith Alpha AAA, Cook, Inc., Bloomington, Indiana) have demonstrated an unexpectedly high incidence of limb graft occlusion (LGO). The purpose of this study was to prospectively evaluate the performance of the Zenith AAA in Japan, with a specific focus on LGO. MATERIALS AND METHODS: All endovascular aneurysm repairs (EVARs) for abdominal aortic aneurysms performed using the Zenith Alpha AAA from July 2020 to October 2021 in 23 Japanese hospitals were prospectively evaluated. All computed tomographic images were analyzed in the core laboratory. Late complications were defined as any aneurysm-related events occurring >30 days after EVAR, including aneurysm sac enlargement of >5 mm and any reinterventions performed. Endoleaks without sac enlargement or reintervention were excluded as late complications. RESULTS: During the study period, 147 EVARs were performed using the Zenith Alpha AAA. The mean patient age was 76.5±7.7 years, 84.4% of patients were male, and the mean aneurysm diameter was 52.4±9.2 mm. Instruction-for-use violations were observed in 76 patients (51.7%), primarily associated with a severely angulated proximal neck (>60°). There were six intraoperative complications and 62 additional intraoperative treatments reported, most of which involved preemptive coil embolization of the inferior mesenteric artery (37 cases). Technical success, defined as the absence of type 1 or 3 endoleaks on final angiography, was achieved in 99.3% of patients. At 12 months, there was only one case of type 1/3 endoleak (0.8%) and one aneurysm sac enlargement exceeding 5 mm (0.8%); however, a high incidence of type 2 endoleaks was observed in 35.2% of patients, and aneurysm sac regression exceeding 5 mm was achieved in 30.1% of patients. Nine late complications were observed, and the rate of freedom from late complications at 12 months was 93.5%, encompassing four LGOs and one limb graft stenosis (3.4%). CONCLUSIONS: In contrast to recent reports, our Japanese multicenter prospective study demonstrated satisfactory early clinical results, including an acceptable LGO rate, for the low-profile Zenith Alpha AAA. Long-term follow-ups will be performed to confirm the persistence of these outcomes.Clinical ImpactThis study prospectively evaluated the performance of 147 Zenith Alpha AAAs used for endovascular aneurysm repair with core-lab adjudication focusing especially on limb graft occlusion (LGO). At 12 months, aneurysm sac regression exceeding 5 mm was achieved in 30.1% of patients, and there was only one type 1/3 endoleak, one aneurysm sac enlargement (>5 mm), and nine late complications including five LGOs (3.4%), resulting in rate of freedom from late complications at 93.5%. Satisfactory early clinical results, including an acceptable rate of LGO can be achieved, particularly with cautious usage of the Zenith Alpha Spiral-Z Endovascular Leg." 5mm), and nine late complications including five LGOs (3.4%), resulting in rate of freedom from late complications at 93.5%. Satisfactory early clinical results, including an acceptable rate of LGO can be achieved, particularly with cautious usage of the Zenith Alpha Spiral-Z Endovascular Leg.
引用
- Fujimura N, Ichihashi S, Shibata T, et al. Early Clinical Results From the Japanese Prospective Multicenter Study to Evaluate Zenith Alpha Abdominal Stent Graft for Abdominal Aortic Aneurysm (JUSTICE) Registry Demonstrate Acceptable Limb Patency at 12 Months. J Endovasc Ther. 2024. PMID: 38654524. doi:10.1177/15266028241248311
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。